Metabolic pathways are intricate to the underlying pathology for AD, as suggested by genetic, epidemilogical and in vitro studies. Approximately 50% of all AD patients are carriers of the E4 allele of apolipoprotein E, involved in lipid metabolism, compared to 2% of the general population. The majority of AD patients are characterized by some form of insulin abnormality (insulin resistance, hyperinsulinemia or even type II diabetes). FDG-PET scans show abnormal glucose utilization in brains of patients even before the onset of dementia.

Neurotez is focused in the identification and characterization of factors relevant to obesity and/or the metabolic syndrome that modulate brain aging or the conversion of normal brain aging to that hampered with AD.